Objective: Publication of the Women's Health Initiative (WHI) study has changed our understanding on the effects of hormone replacement therapy. This study was designed to evaluate patterns of antiosteoporosis medication (AOM) use in a Medicaid population before and after the release of the WHI study results. Results: The overall prevalence of AOM did not change between pre-WHI and post-WHI study publication. However, there were significant changes in the prevalence of certain AOM drug classes. Estrogen use decreased significantly after the WHI study release for all age and racial groups. The prevalence for bisphosphonates and SERM increased significantly in the post-WHI period.
INTRODUCTION T
HE WOMEN'S HEALTH INITIATIVE (WHI) study established that hormone therapy (HT) containing estrogen plus progestin increased postmenopausal women's risk of breast cancer, stroke and myocardial infarction. 1 The study was stopped 3 years early because of this finding. 1 Although the study reported a decreased risk of hip fractures, the U.S. Food and Drug Administration (FDA) concluded that HT should be considered only for women at significant risk of osteoporosis who cannot take nonestrogen medications. 2 The FDA approved the following drug classes for osteoporosis prevention or treatment or both: bisphosphonates (alendronate, risedronate), salmon calcitonin, estrogen, raloxifene, and teriparatide. 3 One more bisphosphonate, ibandronate, has since been approved by the FDA. 4 Of these agents, only estrogen is approved for prevention but not for treatment of osteoporosis. Following publication of the WHI, the FDA recommended HT use at the lowest doses and for the shortest duration of time. 5 However, HT plays an important role in women's health for controlling postmenopausal symptoms, and estrogen certainly adds the benefit of preventing osteoporosis for those women who are on an HT regimen with the indication of postmenopausal symptoms. Because osteoporosis is a disease requiring long-term treatment if not prevented, women will likely need to be shifted from HT to other antiosteoporosis medications (AOMs) in order to continuously receive the beneficial effects of drug therapy on bone. Given the important therapeutic recommendations of the WHI publication and the documented impact of the study on HT use by several studies, [6] [7] [8] [9] [10] [11] it is important to understand how these changes affect the management of osteoporosis in a vulnerable population, such as Medicaid recipients, with a lower socioeconomic status. The primary goal of this study was to evaluate the extent of osteoporosis prevention and treatment with AOM before and after release of the WHI results. AOM use was assessed by AOM category, further evaluated by comparing estrogen and nonestrogen agents, and described by recipient characteristics, such as age and race.
MATERIALS AND METHODS

Study population and data source
A descriptive time series analysis was conducted to evaluate the immediate impact of the WHI publication on the use of AOM in women 50 years of age and older who were enrolled in the Pennsylvania Medicaid program from December 1, 2001, through December 31, 2002. The study included only fee-for-service recipients, as data for recipients enrolled in the managed care programs were not available at the time of the analyses. Once all the recipients were identified, program eligibility and pharmacy claims data were extracted for all women enrolled at any time in the program during the study period. Comparisons of AOM claim records were made based on two different time periods: pre-WHI and post-WHI. As the WHI study was published on July 17, 2002 
Target drugs and prevalence estimation
All dosage forms and routes of administration for all prescription AOM medications were identified, including estrogens, bisphosphonates, selective estrogen receptor modulator (SERM), and calcitonin. 6 As the study focused only on the antiresorptive properties of estrogens in HT formulations, we excluded drug entities containing only progesterone as a single agent and combination products of progesterone without estrogens. We included alendronate, risedronate, etidronate, pamidronate, tiludronate, and zoledronate as bisphosphonates. Of these, only alendronate and risedronate were approved for osteoporosis prevention and treatment by the FDA during the study time frame. Our intent, however, was focused on evaluating potential benefits from all types of AOMs on bone health rather than assessing appropriate use of AOM therapy according to FDA guidelines. Both injectable and nasal spray forms of salmon calcitonins are included in the calcitonin class. Only raloxifene was included in the SERM class. Because teriparatide was approved by the FDA in November 2002, 1 month prior to the end of our study period, it was not included in the study.
A recipient was defined as an AOM user if she had at least one AOM claim record in a month. As the number of enrollees fluctuated during the study period, we used prevalence as our major outcome measure rather than reporting only absolute numbers of recipients per month. Drugspecific prevalence was defined as the proportion of women with one or more prescriptions for the drug or drug class of interest during the month. Monthly age-stratified prevalence of drug use was defined as the proportion of eligible women within each age stratum receiving one or more prescriptions for the drug or drug combination. Demographic characteristics of the recipients included age and race. Age was categorized in 10-year intervals (50-59 years, 60-69 years, 70-79 years, Ն80 years). Race was categorized as Caucasian, African American, or other. To assess changes in patterns of AOM prescriptions that were not related to the release of the WHI study, antidiabetic agents were selected as a comparison drug class. Antidiabetic medications were chosen as the comparison drug class because we believed that this class of medications would not be affected by the WHI publication during the study period. Diabetes medications included insulin and oral hypoglycemic agents (alpha-glucosidase inhibitors, biguanides, insulin-release stimulants, and insulin-response enhancers).
Statistical analyses
Changes in AOM prescription prevalence over time were evaluated using graphs with R 2.1.0 software. (The R Foundation for Statistical Computing, Vienna, Austria). Student's t tests were used to compare the average monthly prevalence of each AOM drug class between pre-WHI and post-WHI study periods. Comparisons were made for overall AOM use, by AOM drug class, as well as by recipient characteristics of age and race. Similar comparisons were made for antidiabetic agent use in the same period. Simple linear regression analyses were conducted to compare changes in slopes between the two time periods for the prevalence of each drug class. All statistical analyses were conducted using SAS version 9.1.3 (Cary, NC) The a priori significance level for all statistical analyses was set at 0.05.
RESULTS
An estimated monthly average of 247,993 (SD 25,577) women were enrolled in the Pennsylvania Medicaid fee-for-service program during the study period. Of those, approximately 35% were Ն50 years (84,687 Ϯ 4,079 women per month) ( Table 1) . During the study period, enrollment in the fee-forservice program decreased because of a shift of recipients to the managed care program. The overall prevalence of AOM was approximately 14.7%. About 40% of the AOM users were women in the oldest age category (Ն80 years), and 93% of the AOM users were Caucasian ( Table 1) .
The prevalence of AOM users is listed and further evaluated by age, race, and type of AOM in Table 2 . Overall prevalence of AOM use did not change between pre-WHI and post-WHI (p ϭ 0.190) ( Table 2 ). There was a statistically significant decrease in estrogen prevalence (p Ͻ 0.001) after the WHI publication (Table 2 ). This decrease in estrogen prevalence was observed across all age and racial groups (p Ͻ 0.001). The reduction in estrogen prevalence was highest among women Ն80 years (Ϫ29.6%) and other racial group (Ϫ38.2%) compared with other age groups and with Caucasian and African Americans, respectively.
There was a statistically significant increase in the prevalence of all types of nonestrogen AOM, except for calcitonin (Table 2) . When the use of nonestrogen AOM was further analyzed by recipient characteristics, bisphosphonate prevalence increased in all age groups and racial groups post-WHI compared with pre-WHI. Similarly, raloxifene prevalence was significantly increased post-WHI in Caucasian and African American groups and all age groups except for women in their 70s. Figure 1 depicts graphic changes in the prevalence of estrogen and nonestrogen AOMs over time and summarizes changes in the slopes before and after the WHI publication. Changes in trends of estrogen and bisphosphonate use started before the WHI publication. Further significant reductions in estrogen use occurred post-WHI (slope Ϫ0.78 in pre-WHI vs. slope Ϫ2.10 in post-WHI). Bisphosphonate prevalence was increasing both before and after WHI publication (slope ϩ1.35 in pre-WHI vs. slope ϩ0.46 in post-WHI). Figure 2 shows the distribution and the most common forms of bone-protecting agents used in our study population by age group. The choice of AOM class varied by the recipient's age. The proportion of bisphosphonate users increased from 16% in women of 50-59 years to 45% in women Ն80 years. The use of calcitonin was also increased from 4% to 35% in respective age groups. Conversely, the proportion of estrogen users declined with increasing age (73% of women age 50-59 years vs. 11% of women age Ն80 years). When use of antidiabetic medications was evaluated as the comparison drug class, there was an increase in the prevalence of antidiabetic medication users between pre-WHI and post-WHI (18.5% vs. 19.1%). However, simple linear regression analyses showed that the changes in the slope for antidiabetes medication prevalence before and after the WHI publication were not statistically significant (p ϭ 0.3930).
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DISCUSSION
These descriptive analyses were conducted to assess the impact of the results of a major clinical trial about HT within a subset of the Medicaid population. The findings from this study show that after WHI publication, (1) the overall AOM prevalence was 15% and did not change throughout the study period, (2) estrogen prevalence declined, and nonestrogen AOM increased, and (3) the patterns of AOM prescribing changed.
According to recent data published by the American Association of Clinical Endocrinologists for the prevention and treatment of postmenopausal osteoporosis, 3 fewer than one third of the cases of osteoporosis have been diagnosed, and only one seventh of American women with osteoporosis receive treatment. Studies document that osteoporosis is underrecognized and undertreated both in the United States [12] [13] [14] [15] and in other countries. 16, 17 Newer AOMs offer improved efficacy and a streamlined dosing schedule, allowing for potential improvement in medication compliance. Our study indicated only 15% of women were prescribed an AOM. Although AOM therapy is not recommended for all postmenopausal women with osteopenia-with a prevalence of osteoporosis or osteopenia estimated at 55% among people aged Ն50 in the United States 18 -our findings about the prevalence of overall AOM use support the concern that osteoporosis is still undertreated, at least for women from this Medicaid fee-for-service population.
Even though overall recognition of the disease is less than optimal, it is encouraging that there was no reduction in overall AOM use after the WHI publication. One of the major concerns about osteoporosis management after the WHI publication was the possibility of a drastic reduction in the overall prevalence of bone protection in postmenopausal women as a result of discontinuation of HT. As expected, a reduction in HT use after the WHI publication was reported in a few studies. [6] [7] [8] [9] [10] [11] Our study findings showed no apparent changes in overall AOM prevalence, reduction in LEE ET AL. 158 estrogen use, and increases in nonestrogen type AOM, suggesting a potential switch from estrogen to nonestrogen type AOM modalities, although we did not evaluate the switching issue on an individual prescription level. Another recently published study showed that the number of prescriptions with new AOMs, such as bisphosphonates, had been increasing since the release of these agents. 19 However, additional studies are needed to see if this trend continues on a long-term basis, if the switching occurred from estrogen to nonestrogen type AOM modalities, and if the recognition and treatment of osteoporosis is improved in our study population. During the period immediately before the WHI publication, estrogen was the most prevalent form of AOM prescribed in our population regardless of the primary indication for the therapy, and bisphosphonate was the second prevalent form. However, this pattern was reversed after publication of the WHI report. In a previous study conducted by the current researchers assessing the extent of osteoporosis prevention and treatment by AOM in U.S. ambulatory care settings, a similar pattern was observed; estrogen was the most prevalent form of bone-protecting agent among postmenopausal women in 1997 and 1998. 12 It was expected that this pattern would shift to nonestrogen therapies, such as bisphosphonates and SERM, for osteoporosis prevention. 12 Although the current study is not designed to evaluate a shift of AOM modalities at the individual patient level (i.e., a change in prescription from estrogen to other form of AOM prescription in individual recipients' profiles), changes at the population level indicate that a shift from estrogen to nonestrogen modalities occurred in this Medicaid population.
Trends in estrogen and bisphosphonate prevalence started becoming evident right before the WHI publication (Fig. 1) . These changes in AOM use could have occurred because the WHI report was prereleased on the Internet and heavily publicized by the media before publication. Further, a reduction in the slope value for estrogen after publication suggests that the prevalence declined at a faster rate after the WHI publication. This notable reduction in estrogen prevalence after the WHI publication suggests an impact of the WHI publication on estrogen use. Our additional analysis using antidiabetic medications as the comparison drug class shows that the use of antidiabetic medication did not change at the time of the WHI publication, suggesting that there was not some other factor influencing general medication prescribing practices at the time of the WHI publication. This finding further supports the conclusion that dissemination of the WHI study results was responsible for the observed changes in patterns of AOM use. In terms of bisphosphonate use, our results corroborate the increase in bisphosphonate use during this time period noted by Stafford et al. 19 A few limitations should be considered when interpreting the results of our study. This study did not include teriparatide as one of AOMs, as the drug was approved right before our study period ended. We believe, however, that the exclusion of teriparatide would not change our conclusions on overall AOM prevalence or nonestrogen AOM because it would affect only the last month of the study period, and 1 month may not be a sufficient time for a new drug to be fully marketed.
Lack of information on diagnosis of osteoporosis is another limitation. Evaluating appropriate therapy for osteoporosis treatment after formal diagnosis was not the purpose of our study. Our primary intention was to assess the extent of bone protection, that is, osteoporosis prevention and treatment, by using any AOM regardless of the primary indication of each AOM. Therefore, we did not attempt to identify patients with a diagnosis of osteoporosis. Information about all AOMs was collected from prescription claims, not a chart review or patient survey. Therefore, information about such issues as drug indication, rationale for drug discontinuation, concomitant disease states, type of prescribers, and patient preferences was not available. However, prescription claims do indicate drug availability and have been shown to be a reliable source of drug exposure. 20 Additionally, generalizability of the study findings to other population is limited to other Medicaid programs or even within the Pennsylvania Medicaid program because the Pennsylvania Medicaid fee-forservice program consists primarily of a rural pop- ulation, and only a proportion of the Medicaid recipients were included in the analysis.
CONCLUSIONS
With the unique advantages of administrative claims data, an immediate impact of a nationallevel outcomes trial on physician's prescribing patterns and drug use is documented. After a major clinical trial reported the effects of HT on primary prevention of cardiovascular diseases, breast cancer, and osteoporosis, the use of nonestrogen AOMs increased within a short period in the Pennsylvania Medicaid program. This study suggests that the WHI study affected patterns of AOM use, resulting in reduction of estrogen and increase of nonestrogen AOMs among women enrolled in a Medicaid program.
